- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.08. | FDA grants RPDD to ReviR's RTX-117 for CMT | ||
| 27.08. | ViiV Healthcare's Tivicay PD gains FDA approval for paediatric HIV therapy | ||
| 26.08. | RevMed's pancreatic cancer drug breezes through with swift approval | ||
| 26.08. | Metsera backers establish new biotech armed with China-licensed immunology asset | ||
| 26.08. | Jazz secures FDA approval for Ziihera in advanced HER2+ GEA | ||
| 26.08. | ESC 2026: Common pharma excipient linked to uptick in cardiovascular risk | ||
| 26.08. | McKesson to acquire Precision Medicine Group for $2.25bn | ||
| 25.08. | J&J's Imaavy secures expanded US approval in rare blood disorder | ||
| 25.08. | FDA places clinical hold on Regenxbio's RGX-121 in MPS II trial | ||
| 25.08. | GSK snags Japanese approval for first hepatitis B functional cure, Hibsago | ||
| 25.08. | Lundbeck's asedebart receives EC orphan designation in Cushing's syndrome | ||
| 25.08. | Takeda's Orzeyful secured Japan MHLW approval for narcolepsy type 1 | ||
| 24.08. | Roche outlays $2.3bn for Hanmi's non-GLP-1 obesity candidate | ||
| 24.08. | Analysts praise intismeran's landmark Phase III win, look to further data | ||
| 24.08. | Gossamer Bio announces $250m in funding to advance seralutinib | ||
| 24.08. | Johnson & Johnson's multiple myeloma treatment secures EC approval | ||
| 21.08. | Roche commits $750m to double Oregon-based US manufacturing capacity | ||
| 21.08. | Eli Lilly's weekly insulin jab Onswik set for NHS use if approved | ||
| 21.08. | WellSpan and Johns Hopkins renew partnership for advanced cancer care access | ||
| 21.08. | Charles River and MVC to develop enterovirus vaccine | ||
| 20.08. | Regeneron's Pasatru wins FDA approval in ultra-rare 'stone man disease' | ||
| 20.08. | Kynexis pockets €97m to advance cognition-focused schizophrenia drug | ||
| 20.08. | FDA grants accelerated approval to Ultragenyx's Genglycos gene therapy | ||
| 20.08. | SandboxAQ introduces AQPotency for virtual drug screening | ||
| 19.08. | BioMarin spends up to $490m for Alesta's bone disease candidate |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.